Вакцина БЦЖ до сих пор остается «золотым стандартом» и является единственным препаратом, применяемым для иммунизации против туберкулеза. Вакцинация БЦЖ обязательна в 64 странах мира и официально рекомендована в 118 странах. Ревакцинацию БЦЖ проводят лишь 59 стран в мире. Вакцинация БЦЖ проведена приблизительно у 2 млрд, человек всех возрастов и остается основной формой профилактики туберкулеза в большинстве стран, предупреждая развитие тяжелых форм заболевания, связанных с гематогенным распространением микобактерий. Иммунизация БЦЖ снижает смертность от туберкулеза у детей на 75-80%.
Цель каждой вакцинации состоит в создании иммунологической памяти, так чтобы при встрече с инфекцией можно было избежать клинического проявления заболевания.
This article describes data on the immunogenicity of sheep echinococcos vaccine
The article presents the results of scientific research on testing the vaccine - "Enterovak - 5" in the farm of the Kushtepa district of the Fergana region "Yokub ota". The results of determining the dynamics of the titer of antiviral and bacterial antibodies in the blood serum of cows when immunized with the associated inactivated vaccine “Enterovak - 5” are given. It has been established that immunized cows have significantly increased antibodies both against viruses - causative agents of viral infections, and against Escherichia and Proteus
Human papillomavirus infection is the most common viral infection of the reproductive tract and can cause cervical cancer in women, other cancers and genital warts in both men and women. The article describes the epidemiological situation in a retrospective aspect, discusses the experience of using vaccines against human papillomavirus in the world, the CIS countries and the Republic of Kazakhstan, the results of research work on the success of this vaccine. According to WHO, in 2018 new cases of cervical cancer accounted for 3.2% of all cancers in the world, which justifies the priority of studying this problem.
The cited authors note the oncogenic potential of genotypes 16 and 18 of papillomavirus in the occurrence of approximately 70% of all cases of invasive cervical cancer worldwide. Vaccine prophylaxis has been proven to be effective and safe as a promising primary approach to cancer prevention, and barriers to vaccine access must be removed to achieve vaccination goals
This article describes data on the immunogeneticity of the sheep echinococcosis vaccine